AI Article Synopsis
- A case of adult acute myeloid leukemia was identified with a new genetic abnormality involving a translocation between chromosome 11 and 12, which affects the NUP98 gene without involving the HOXC gene cluster.
- Researchers developed a specialized double-color double-fusion FISH assay to distinguish this specific translocation from others that also affect NUP98 but involve HOXC11 or HOXC13.
- The study found potential partner genes (RARG, MFSD5, and ESPL1) associated with this translocation, with ESPL1 being the only one previously linked to human cancers, highlighting the assay's potential for diagnosing NUP98-positive leukemias.
Article Abstract
We report a case of adult acute myeloid leukemia with a new t(11;12)(p15;q13) underlying a NUP98 rearrangement without HOXC cluster gene involvement. We designed a specific double-color double-fusion FISH assay to discriminate between this t(11;12)(p15;q13) and those producing NUP98-HOXC11 or NUP98-HOXC13. Our fluorescence in situ hybridization (FISH) showed that putative candidate partners mapping 600 kilobases centromeric to HOXC were RARG (retinoic acid receptor gamma), MFSD5 (major facilitator superfamily domain containing 5), and ESPL1 (extra spindle pole bodies homolog 1). It is noteworthy that so far only ESPL1 has been implicated in human cancers. This FISH assay is useful for diagnostic screening of NUP98-positive leukemias.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cancergencyto.2009.04.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rapamycin and Niacin combination induces apoptosis and cell cycle arrest through autophagy activation on acute myeloid leukemia cells.
Mol Biol Rep
December 2024
Faculty of Life and Natural Sciences, Department of Bioengineering, Abdullah Gül University, Sumer Campus, Kayseri, 38080, Turkey.
Background: Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy caused by disorders in stem cell differentiation and excessive proliferation resulting in clonal expansion of dysfunctional cells called myeloid blasts. The combination of chemotherapeutic agents with natural product-based molecules is promising in the treatment of AML. In this study, we aim to investigate the anti-cancer effect of Rapamycin and Niacin combination on THP-1 and NB4 AML cell lines.
View Article and Find Full Text PDFINWORKS and Hiroshima/Nagasaki Leukaemia Results.
Dose Response
December 2024
Canadian Nuclear Laboratories - Retired, Chalk River, ON, Canada.
The Hiroshima/Nagasaki (H/N) studies by the Radiation Effect Research Foundation have not shown increased leukaemia for acute doses below 200 milli-gray (mGy). By contrast the INWORKS study of leukaemia in workers stated: "This study provides strong evidence of positive associations between protracted low-dose radiation exposure and leukemia". The INWORKS study also claimed increased leukaemia, not including Chronic Lymphocytic Leukaemia, at cumulative occupational doses of less than 100 mGy.
View Article and Find Full Text PDFOne hallmark of cancer is the upregulation and dependency on glucose metabolism to fuel macromolecule biosynthesis and rapid proliferation. Despite significant pre-clinical effort to exploit this pathway, additional mechanistic insights are necessary to prioritize the diversity of metabolic adaptations upon acute loss of glucose metabolism. Here, we investigated a potent small molecule inhibitor to Class I glucose transporters, KL-11743, using glycolytic leukemia cell lines and patient-based model systems.
View Article and Find Full Text PDFAcute Myeloid Leukemia (AML) is an aggressive cancer with dismal outcomes, vast subtype heterogeneity, and suboptimal risk stratification. In this study, we harmonized DNA methylation data from 3,314 patients across 11 cohorts to develop the Acute Leukemia Methylome Atlas (ALMA) of diagnostic relevance that predicted 27 WHO 2022 acute leukemia subtypes with an overall accuracy of 96.3% in discovery and 90.
View Article and Find Full Text PDFAdoptive cell therapy (ACT) can address an unmet clinical need for patients with relapsed/refractory acute myeloid leukemia (AML), but its effect is often modest in the setting of high tumor burden. In this study, we postulated that strategies to lower the AML apoptotic threshold will augment T cell killing of AML cells. BH3 mimetics, such as venetoclax, are a clinically approved class of compounds that predispose cells to intrinsic apoptosis by inhibiting anti-apoptotic mitochondrial proteins.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!